Please login to the form below

Not currently logged in
Email:
Password:

BioCryst Appoints new senior vice-president of regulatory affairs

US-based BioCryst Pharmaceuticals hires Dr Elliott T Berger as senior vice-president of regulatory affairs

US-based BioCryst Pharmaceuticals has hired Dr Elliott T Berger as senior vice-president of regulatory affairs.

Dr Berger brings to BioCryst a long and successful track record in obtaining approval from the FDA for numerous drugs. He will play an integral role in BioCryst's planned clinical research programmes for treatments for influenza, leukaemia and lymphoma, autoimmune diseases and transplant rejection, and will work in close collaboration with health authorities in the US and other countries.

Berger has more than 30 years of experience in the pharmaceutical industry, including over 25 years devoted to management of regulatory affairs supporting new drug and biologic development. Most recently he was vice-president of regulatory affairs and quality assurance and head of global regulatory strategy at EMD Pharmaceuticals, the North American subsidiary of Germany-headquartered Merck KGaA.

Berger held a variety of research positions at Merck Research Laboratories in West Point, Pennsylvania, most recently as Senior Director, Regulatory Liaison. He has submitted and managed over 10 New Drug Applications and numerous Investigational Drug Applications in the areas of oncology, diabetes, cardiovascular disease, and neurology.

8th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics